SGHT

Sight Sciences Inc

Add to Watchlist

Advanced Chart

5.100

+0.04(0.791%)1D

Line

Candle

YTD

High

5.160

Open

5.080

VWAP

5.07

Vol

60.23K

Mkt Cap

267.07M

Low

4.980

Amount

305.29K

EV/EBITDA(TTM)

Total Shares

49.76M

203.30M

EV/OCF(TTM)

P/S(TTM)

3.39

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

19.45M

+11.09%

-0.207

-26.24%

19.22M

+0.75%

-0.247

+7.44%

17.74M

-11.97%

-0.261

+18.47%

Estimates Revision

The market is revising Upward the revenue expectations for Sight Sciences, Inc. (SGHT) for FY2025, with the revenue forecasts being adjusted by 2.73% over the past three months. During the same period, the stock price has changed by 46.97%.

Revenue Estimates for FY2025

Revise Upward

+2.73%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-6.3%

In Past 3 Month

Stock Price

Go Up

+46.97%

In Past 3 Month

7 Analyst Rating

-8.43% Downside

Wall Street analysts forecast SGHT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGHT is 4.67 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

4 Hold

0 Sell

Moderate Buy

-8.43% Downside

Current: 5.100

Low

4.00

Averages

4.67

High

7.00

-8.43% Downside

Current: 5.100

Low

4.00

Averages

4.67

High

7.00

Lake Street

Buy

maintain

$5 -> $7

2025-10-21

Reason

Lake Street

Price Target

$5 -> $7

2025-10-21

maintain

Buy

Reason

Lake Street raised the firm's price target on Sight Sciences to $7 from $5 and keeps a Buy rating on the shares after two Medicare administrative contractors finalized coverage policies for Sight Sciences' Dry Eye Disease treatment system, TearCare. The firm sees this as "a significant positive that could be a driver of outperformance," the analyst tells investors.

Citi

Neutral

maintain

2025-08-21

Reason

Citi

Price Target

2025-08-21

maintain

Neutral

Reason

Citi raised the firm's price target on Sight Sciences to $4.50 from $3.60 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology space following the Q2 reports. Citi views the overall sector as healthy and opened "positive catalyst watches" on Edwards Lifesciences (EW) and Penumbra (PEN). The analyst also added iRhythm (IRTC) to its medtech top picks list, alongside Boston Scientific (BSX) and Edwards.

Lake Street

Hold

Buy

upgrade

$3 -> $5

2025-08-08

Reason

Lake Street

Price Target

$3 -> $5

2025-08-08

upgrade

Hold

Buy

Reason

Morgan Stanley

Equal Weight

maintain

$3 -> $4

2025-07-15

Reason

Morgan Stanley

Price Target

$3 -> $4

2025-07-15

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Sight Sciences to $4 from $3 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.

Piper Sandler

Matt O'Brien

Neutral

maintain

2025-06-19

Reason

Piper Sandler

Matt O'Brien

Price Target

2025-06-19

maintain

Neutral

Reason

Piper Sandler analyst Matt O'Brien raised the firm's price target on Sight Sciences to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes shares of Sight Sciences have seen some recovery year-to-date, up +10.7% after a challenging 2024 campaign. Piper likes the company's MIGS technology and views the company's dry eye asset as an intriguing product in a large end-market, but it wrestles with uncertainty in the glaucoma business, namely the late '24 LCD reimbursement change and potential trialing of a recent competitor product launch. Further, Piper suspects Sight Sciences will need to access the capital markets in the next 1-2 years, and it thinks it will take dry eye at least several quarters to find its stride with the change in commercial/reimbursement strategy.

Citi

Neutral

maintain

2025-05-22

Reason

Citi

Price Target

2025-05-22

maintain

Neutral

Reason

Citi raised the firm's price target on Sight Sciences to $3.60 from $3.20 and keeps a Neutral rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Sight Sciences Inc (SGHT.O) is -5.57, compared to its 5-year average forward P/E of -7.14. For a more detailed relative valuation and DCF analysis to assess Sight Sciences Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.14

Current PE

-5.57

Overvalued PE

-2.59

Undervalued PE

-11.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.13

Current EV/EBITDA

-6.96

Overvalued EV/EBITDA

0.54

Undervalued EV/EBITDA

-12.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.98

Current PS

5.06

Overvalued PS

11.86

Undervalued PS

0.11